Qizhen Shi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7922175/publications.pdf

Version: 2024-02-01

46 papers	1,179 citations	516710 16 h-index	395702 33 g-index
46 all docs	46 docs citations	46 times ranked	801 citing authors

#	Article	IF	Citations
1	A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD. Blood Advances, 2022, 6, 2778-2790.	5.2	1
2	Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. Frontiers in Immunology, 2022, 13, 810620.	4.8	3
3	Blocking hemophilic arthropathy. Blood, 2022, 139, 2734-2735.	1.4	2
4	In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy. Journal of Cellular Physiology, 2021, 236, 354-365.	4.1	7
5	Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells. Molecular Therapy - Nucleic Acids, 2021, 23, 719-730.	5.1	4
6	Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity. Blood Advances, 2021, 5, 1224-1238.	5.2	3
7	Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics. Journal of Thrombosis and Haemostasis, 2021, 19, 2417-2427.	3.8	5
8	In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A. Haematologica, 2020, 105, e175-e179.	3.5	9
9	Utilizing Platelets as a Targeted for Gene Therapy of Hemophilia a and Hemophilia B. Microscopy and Microanalysis, 2020, 26, 826-827.	0.4	0
10	Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. Blood Advances, 2020, 4, 2272-2285.	5.2	3
11	Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A. Frontiers in Immunology, 2020, 11, 964.	4.8	5
12	The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression. Blood Advances, 2020, 4, 55-65.	5.2	13
13	A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 64-71.	2.3	2
14	Platelet-Targeted Gene Therapy Induces Robust Immune Tolerance Even in a Primed Model Via Peripheral Clonal Deletion of CD4 and CD8 T Cells and Expansion of Treg Cells. Blood, 2020, 136, 2-2.	1.4	0
15	Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. Blood Advances, 2019, 3, 2700-2711.	5.2	39
16	Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. Blood Advances, 2019, 3, 3099-3110.	5.2	28
17	The impact of GPIbÎ± on plateletâ€targeted FVIII gene therapy in hemophilia A mice with preâ€existing antiâ€FVIII immunity. Journal of Thrombosis and Haemostasis, 2019, 17, 449-459.	3.8	14
18	Animal Models Demonstrate a Critical Role of Factor VIII in Par4- and Platelet-Mediated Pathology. Blood, 2019, 134, 1057-1057.	1.4	0

#	Article	IF	Citations
19	Platelet-Targeted Gene Therapy for Hemophilia. Molecular Therapy - Methods and Clinical Development, 2018, 9, 100-108.	4.1	29
20	Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells. Frontiers in Immunology, 2018, 9, 1950.	4.8	12
21	In Vivo Enrichment of Genetically Manipulated Platelets for Murine Haemophilia B Gene Therapy. Blood, 2018, 132, 3483-3483.	1.4	0
22	The impact of von Willebrand factor on factor VIII memory immune responses. Blood Advances, 2017, 1, 1565-1574.	5.2	10
23	TGF-Î²1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. Blood Advances, 2016, 1, 139-151.	5.2	18
24	The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity. Blood, 2016, 127, 1346-1354.	1.4	21
25	The Impact of VWF on FVIII Immune Responses in Hemophilia a Mice with Pre-Existing Anti-FVIII Immunity. Blood, 2016, 128, 84-84.	1.4	0
26	A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood, 2014, 123, 3706-3713.	1.4	145
27	Platelet Gene Therapy by Lentiviral Gene Delivery to Hematopoietic Stem Cells Restores Hemostasis and Induces Humoral Immune Tolerance in FIXnull Mice. Molecular Therapy, 2014, 22, 169-177.	8.2	53
28	Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. Blood, 2014, 123, 395-403.	1.4	50
29	The Immunogenicity of Platelet-Derived FVIII in Hemophilia a Mice with or without Pre-Existing Anti-FVIII Immunity. Blood, 2014, 124, 2809-2809.	1.4	0
30	Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nature Communications, 2013, 4, 2773.	12.8	102
31	In Vivo Selection Of Genetically Manipulated Hematopoietic Stem Cells For Platelet Gene Therapy Of Hemophilia A. Blood, 2013, 122, 2329-2329.	1.4	0
32	Correction of Murine Bernardâ€“Soulier Syndrome by Lentivirus-mediated Gene Therapy. Molecular Therapy, 2012, 20, 625-632.	8.2	31
33	Lentivirus-Mediated Platelet Gene Therapy Corrects Bleeding Diathesis and Induces Immune Tolerance in Murine Hemophilia B Mice. Blood, 2012, 120, 1101-1101.	1.4	0
34	Factor IX ectopically expressed in platelets can be stored in Î±-granules and corrects the phenotype of hemophilia B mice. Blood, 2010, 116, 1235-1243.	1.4	54
35	Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. Blood, 2010, 116, 3049-3057.	1.4	48
36	Platelets as delivery systems for disease treatments. Advanced Drug Delivery Reviews, 2010, 62, 1196-1203.	13.7	47

#	Article	IF	Citations
37	De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A. Blood, 2010, 116, 2198-2198.	1.4	1
38	Factor VIII Inhibitors: Von Willebrand Factor Makes A Difference In Vitro and In Vivo. Blood, 2010, 116, 709-709.	1.4	0
39	Platelet-Targeted Expression of Human BDD-FVIII Reduces Bleeding in Canine Hemophilia A.. Blood, 2009, 114, 691-691.	1.4	2
40	Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood, 2008, 112, 2713-2721.	1.4	100
41	Platelet-Targeted Expression of Coagulation Factor VIII (FVIII) Shows Efficacy for Using the Dog as a Large Animal Model for Gene Therapy of Hemophilia a. Blood, 2008, 112, 3525-3525.	1.4	1
42	Ectopic Expression of Human FIX in Mouse Platelets Can Store Releasable FIX in Platelets and May Be a Potential Strategy for Gene Therapy of Hemophilia B.. Blood, 2007, 110, 196-196.	1.4	1
43	Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. Journal of Clinical Investigation, 2006, 116, 1974-1982.	8.2	170
44	Endothelial and Platelet FVIII/VWF Expression - Divergence in Clinical Effect in Murine Models of Hemophilia A with and without FVIII Inhibitory Antibodies.. Blood, 2006, 108, 3286-3286.	1.4	3
45	Transgenic Targeting of Human FVIII Expression to Endothelial Cells Corrects the Murine Hemophilia A Phenotype and Re-Establishes a Releasable Pool of FVIII Together with VWF.. Blood, 2005, 106, 3056-3056.	1.4	0
46	Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood, 2003, 102, 4006-4013.	1.4	143